DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with ...

In order from steepest decline to narrowest, the five unloved were Intel (NASDAQ: INTC), MongoDB (NASDAQ: MDB), Biogen (NASDAQ: BIIB), DexCom (NASDAQ: DXCM), and Microchip Technology (NASDAQ ...

Unless you’re an advocate for health tech or a diabetic like me, you may not have heard of Dexcom or Abbott, the two companies that form an oligopoly in the CGM space. Yet, you’re probably ...

Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...

Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience Co ...

DexCom DXCM has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ...

The key difference is Stelo is available without a prescription. Sean Christensen, Dexcom’s vice president of investor relations, discussed the rationale for launching an OTC device at the ...

Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...